BTIG Maintains Buy on Bright Minds Biosciences, Lowers Price Target to $37
BTIG analyst Thomas Shrader maintains Bright Minds Biosciences (NASDAQ:DRUG) with a Buy and lowers the price target from $147 to $37.
Share
Why It Matters
A stock expert still likes Bright Minds, but thinks it is worth less money now. When experts lower their price targets, it means they see new risks or slower growth ahead.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.